All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the EHA 2022 Congress, the MPN Hub was pleased to speak to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Thrombotic events in MPN: What is the primary prophylaxis used to avoid the first arterial and venous events.
Thrombotic events in MPN: Primary prophylaxis to avoid the first arterial and venous events
Barbui begins by talking about managing thrombotic risk, and how primary prophylaxis can affect the thrombotic risk. Barbui also discusses drugs used to manage thrombosis, including aspirin, interferons, hydroxyurea, and ruxolitinib.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...
Promising preclinical data on combined JAK, PIM, and CDK4/6 inhibition in MPN
Ruxolitinib, a selective inhibitor of Janus kinase 1/2 (JAK1/2), has proven to be beneficial to patients with Philadelphia-chromosome negative myeloproliferative neoplasms...
Subscribe to get the best content related to MPN delivered to your inbox